Back to top

Image: Bigstock

DaVita Inc.

Read MoreHide Full Article

DaVita witnessed impressive results from the Kidney Care business in recent times. As an operating division of the company, DaVita Kidney Care focuses clinical, social and operational practices worldwide. The company’s efforts to control expenses hold promise. A compelling inorganic growth story is positive. The management is also optimistic about new developments in the Kidney Care and HealthCare businesses. However, sluggishness in the Other business is a headwind for DaVita. The company is facing the adverse effects of pricing pressure in the U.S. medical industry and rise in Medicare insurance costs. The company’s major segment — DaVita Medical Group — has been on track for the divestment to Optum. Further, DaVita’s GranuFlo and DaVita Rx units are grappling with multiple issues. These might have a negative impact on the company’s customer base. DaVita underperformed the industry in a year’s time.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

DaVita Inc. (DVA) - free report >>

Published in